UBS Group
CVKD icon

UBS Group’s Cadrenal Therapeutics CVKD Stock Holding History

UBS Group’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.71K Buy
1,112
+1,109
+36,967% +$5.27K ﹤0.01% 9153
2026
Q1 		$15 Sell
3
-1,041
-100% -$7.3K ﹤0.01% 10310
2025
Q4 		$7.08K Buy
1,044
+1,009
+2,883% +$11.4K ﹤0.01% 8478
2025
Q3 		$484 Sell
35
-291
-89% -$3.6K ﹤0.01% 9651
2025
Q2 		$3.93K Sell
326
-8,119
-96% -$121K ﹤0.01% 9308
2025
Q1 		$149K Buy
8,445
+6,273
+289% +$115K ﹤0.01% 6749
2024
Q4 		$31.5K Buy
+2,172
New +$31.4K ﹤0.01% 7570
2023
Q4 		– Sell
-9
Closed -$92 – 9383
2023
Q3 		$92 Buy
+9
New +$128 ﹤0.01% 8907
2023
Q2 		– Sell
-15
Closed -$330 – 8758
2023
Q1 		$324 Buy
+15
New +$457 ﹤0.01% 9074

Other funds holding CVKD

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 26.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return
Q1WB
Quest 10 Wealth Builders Fuquay-Varina, Virginia $129M AUM 22.73% 1-Year Est. Return

UBS Group's CVKD Position: Q2 2026 in Review

UBS Group increased its Cadrenal Therapeutics (CVKD) stake by 36,967% in Q2 2026, buying an estimated $5.27K and bringing the position to 1,112 shares worth $3.71K. The position accounts for ﹤0.01% of the portfolio, ranked #9153.

UBS Group first reported a position in CVKD in Q1 2023 and has held it in 9 quarters since. The position peaked at $149K in Q1 2025. 20 funds tracked by Wall St. Rank hold CVKD as of Q2 2026.

  • UBS Group held 1,112 shares of Cadrenal Therapeutics worth $3.71K as of Q2 2026.
  • UBS Group bought 1,109 Cadrenal Therapeutics shares in Q2 2026, an estimated $5.27K.
  • Cadrenal Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9153 holding.
  • UBS Group first reported a position in Cadrenal Therapeutics in Q1 2023 and has held it in 9 quarters since.
  • UBS Group's Cadrenal Therapeutics position peaked at $149K in Q1 2025.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.